Sep 1, 2025

Selpercatinib in medullary thyroid cancer: RCT shows substantial survival advantages

Following the expiry of the first decision: Reassessment of the drug for the first-line treatment of RET-mutant medullary thyroid cancer shows an indication of a major added benefit.

While over 16% of the patients included in the comparator arm died, only 5% died in the intervention arm. Selpercatinib is therefore a real step forward for patients with thyroid cancer.

Katrin Nink, Head of the Division of Oncology (solid tumours) and Routine Practice Data Collection 09/2025

Selpercatinib is approved for several therapeutic indications, including as monotherapy for the treatment of advanced RET-mutant medullary thyroid cancer in the first line. The drug blocks an enzyme that has mutated in the cancer cells and constantly sends them growth signals. The blockade is intended to prevent the cancer cells from dividing further.

The first benefit assessment in this therapeutic indication ended in 2023 with a temporary decision from the Federal Joint Committee (), because an ongoing randomized controlled trial had not yet delivered any results.

The relevant data are now available, so that the Institute for Quality and Efficiency in Health Care (IQWiG) has been able to conduct a further benefit assessment. The result: Compared with the appropriate comparator therapies vandetanib or cabozantinib, selpercatinib as monotherapy shows numerous and, in some cases, clear advantages. Consequently, there is an indication of a major added benefit of selpercatinib monotherapy.

Advantages in many outcomes

The phase 3 study LIBRETTO-531 was already underway at the time of marketing authorization and the first benefit assessment, but results were not yet available. Informative study results are now available and for the outcome of overall survival there is an indication of a clear added benefit. There are hints of an added benefit in several other outcomes such as fatigue, pain and health-related quality of life. “While over 16% of the patients included in the comparator arm died, only 5% died in the intervention arm,” explains Katrin Nink, Head of the Oncology Division (solid tumours) at IQWiG’s Drug Assessment Department. “Such a clear difference is remarkable.”

The G‑BA decides on the extent of the added benefit

The dossier assessment is part of the early benefit assessment in accordance with the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the . After publication of the dossier assessment, the conducts a commenting procedure and makes a decision on the extent of the added benefit.

Further information from IQWiG:

Media contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form